Current Headlines

  1. Cellular Biomedicine Group's AlloJoin® Therapy For Knee Osteoarthritis (KOA) Becomes The First Stem Cell Drug Application Approved In China For Phase II Clinical Trials

    Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that its off-the-shelf allogeneic adipose-derived mesenchymal progenitor cell (haMPC) AlloJoin® therapy for Knee Osteoarthritis (KOA) has been approved as the first stem cell KOA drug application in China for a Phase II clinical trial

  2. Sandoz Inc. Launches SYMJEPI™ (Epinephrine) In The US

    Sandoz Inc. (Sandoz), a Novartis division, today announced the US market introduction of SYMJEPI™ (epinephrine) 0.3 mg Injection for the emergency treatment of allergic reactions (Type 1), including anaphylaxis

  3. Bridge Biotherapeutics Announces FDA Orphan Drug Designation For BBT-877 In Idiopathic Pulmonary Fibrosis (IPF)

    Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea and a tenant company of JLABS@TMC in Houston, Texas, announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation (ODD) to BBT-877, a drug candidate under development for Idiopathic Pulmonary Fibrosis (IPF) treatment

  4. Visikol Launches OpenLiver™ 3D Cell Culture Models To Accelerate Drug Discovery

    As the leader in 3D cell culture characterization and analysis, Visikol is now expanding their service offering through the introduction of its own liver 3D cell culture models

  5. MDA Awards Venture Philanthropy Grant To AcuraStem To Develop Novel Treatment For ALS

    The Muscular Dystrophy Association has awarded an MDA Venture Philanthropy (MVP) grant totaling $300,000 over two years to AcuraStem Incorporated to support preclinical development of a novel small molecule therapeutic for amyotrophic lateral sclerosis (ALS)

  6. BeiGene Receives U.S. FDA Breakthrough Therapy Designation For Zanubrutinib In Mantle Cell Lymphoma

    BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its investigational Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib, for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy

  7. GenScript Launches Novel Technology Licensed From Amgen For Accelerating Protein And Antibody Purification

    GenScript®, the world's leading gene synthesis provider, announced today at PepTalk that it has launched the AmMag™ SA semi-automatic purification instrument, a novel technology that accelerates and simplifies protein and antibody purification, reducing the process from days to hours

  8. Charles River Laboratories And Atomwise Form A Strategic Alliance To Provide Integrated, Artificial Intelligence-Driven Drug Discovery

    Charles River Laboratories International, Inc. and Atomwise, Inc. recently announced the formation of a strategic alliance that offers clients access to Atomwise’s artificial intelligence (AI)-powered, structure-based, drug design technology, which allows scientists to predict how well a small molecule will bind to a target protein of interest

  9. Ocular Therapeutix Submits Supplemental New Drug Application (sNDA) For DEXTENZA (Dexamethasone Ophthalmic Insert) For The Treatment Of Ocular Inflammation Following Ophthalmic Surgery

    Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for DEXTENZA (dexamethasone ophthalmic insert)

  10. Aptamer Group Announces Agreement With AstraZeneca To Explore Next-Generation Drug Delivery Devices

    Aptamer Group recently announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney. The two-year agreement will give AstraZeneca use of Aptamer Group’s proprietary technology to explore the feasibility of developing the next generation of drug delivery vehicles, called Aptamer Drug Conjugates (ApDCs)